Antimicrobial resistance (AMR) is one of the biggest public health concerns of our time [1] . Currently, resistance has been reported for almost all available antibiotics, from first-line to last-resort drugs [2] . AMR restricts treatment options, leads to increased morbidity and mortality of hospitalized patients and imposes a substantial financial burden on healthcare systems worldwide [3] . The limited pipeline of new antimicrobials and the continuous emergence of multidrug-resistant (MDR) organisms needs to be countered by novel antibacterial strategies coupled with rapid diagnostics to detect resistance, particularly in the case of broad-acting agents such as β-lactams and polymyxins.
a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 expected mass of the antibiotic by a mass-to-charge ratio (m/z) of 18, corresponding to the mass of a water molecule, indicates hydrolysis of the β-lactam ring by an active β-lactamase. This method is approaching use in clinical settings through the development of the MBT STAR-Carba IVD kit for the detection of carbapenemases, led by Bruker. Finally, MALDI-TOF-based identification of resistance has the potential to move beyond specific mechanisms and antibiotics through universal methods based on the indirect detection of bacterial growth by mass spectrometry. These approaches are currently in preliminary stages but have been attempted through the development of the MBT-ASTRA and DOT-MGA assays [10] [11] [12] .
MALDI-TOF mass spectrometry can be used to characterize the lipid A of bacteria
Polymyxin antibiotics (e.g., polymyxin B, colistin) are extremely valuable drugs of last resort that are used to treat challenging bacterial infections [13] . As MDR bacterial strains become more prevalent, the use of colistin is an increasingly important way of managing infections caused by these organisms [14] . This increase in the use of colistin, together with the presence of mobile colistin resistance (MCR) enzymes, which were discovered in 2016 [15] , has contributed to the spread of colistin resistance in gram-negative bacteria and the emergence of extensively drug-resistant organisms [16] . Therefore, as with β-lactamase-mediated resistance, fast detection of colistin resistance is crucial to improved patient outcomes.
Determination of colistin MIC values by broth microdilution, the current gold standard for polymyxin susceptibility testing, is laborious, time-consuming, and sometimes unreliable [15] , while PCR-based approaches cannot keep pace with the emergence of novel mcr genes. In most gram-negative bacteria, colistin resistance arises from chemical modifications to the lipid A portion of their lipopolysaccharide (LPS), mediated by chromosomally encoded mutations or the activity of MCR proteins [17] . Specifically, the addition of a 4-amino-4-deoxy-L-arabinose (L-Ara4N) and/or a phosphoethanolamine (PEtN) moiety to the 4´-and/or 1-phosphate of native lipid A, respectively, results in decreased binding of colistin to the LPS [17] (Fig 1, left column) and emergence of resistance.
The demonstration that lipid A from several gram-negative bacterial species can be detected and its structure characterized by MALDI-TOF mass spectrometry using intact bacterial colonies [19] laid the groundwork for many of the subsequent studies tackling the development of MALDI-TOF-based diagnostics for the rapid detection of colistin resistance. Notably, unlike bacterial identification or detection of β-lactamase activity, which require sample analysis using the positive-ion mode, this approach relies on operating the mass spectrometer in the negative-ion mode, which was not possible on the instruments in routine clinical use until recently [18] .
The MALDIxin test detects colistin resistance from intact Escherichia coli colonies
Chromosomally encoded and MCR-mediated colistin resistance are both prevalent in Escherichia coli clinical isolates [15] . As such, this organism was initially used to demonstrate that rapid detection of resistance is feasible by MALDI-TOF mass spectrometry and to develop the MALDIxin test [20] . The sample preparation step for this approach was shown to be fast and simple. A bacterial colony was suspended and washed in ultra-pure water and subsequently mixed with a super-2,5-dihydroxybenzoic acid (sDHB) matrix directly on the target of a research MALDI-TOF instrument. Data collection using the negative-ion mode allowed direct assessment of whether the tested strain was susceptible or resistant to colistin in less than 15 minutes. For colistin-susceptible strains, only one major peak at m/z 1,796.2, corresponding to [18] . Spectra obtained from colistin-susceptible strains have one major peak at m/z 1,796.2 (top), corresponding to native lipid A. Depending on the mechanism of colistin resistance, spectra from colistin-resistant strains have additional peaks at m/z 1,927. 
(Left column) Structures of the native (top) and modified (middle and bottom) lipid A portion of the Escherichia coli LPS. L-Ara4N (marked in red) and PEtN (marked in blue) modifications to lipid A cause resistance to polymyxin antibiotics. L-Ara4N modification of the 4´-phosphate of native lipid A is characteristic of colistin-resistant E. coli strains carrying chromosomal mutations; this modification often co-occurs with PEtN modification of the 1-phosphate of the lipid A structure. Lipid A from strains expressing MCR enzymes is only modified by PEtN. (Right column) Lipid A spectra obtained from intact E. coli colonies using the MALDI Biotyper Sirius system (Bruker Daltonics) and the adapted MALDIxin protocol
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native lipid A, was detected, whereas for colistin-resistant strains, an additional peak at m/z 1,919.2 was present; the latter arises from the addition of a PEtN moiety to the 1-phosphate group of lipid A (Fig 1, left column, bottom panel). A metric termed polymyxin resistance ratio (PRR), i.e., the ratio of the sum of the intensities of peaks associated with modified lipid A over the intensity of the peak of native lipid A, was introduced and validated on a panel of E. coli strains; colistin-susceptible strains had a PRR of zero, whereas colistin-resistant strains had a positive PRR. Blind validation of the method using a collection of 78 E. coli isolates further supported that MALDI-TOF-based diagnostics hold great promise for rapid, high-throughput and low-cost detection of colistin resistance.
MALDI-TOF mass spectrometry detects resistance in other gram-negative bacterial species
As modification of lipid A is the most common mechanism of colistin resistance in gram-negative bacteria [17] , and the lipid A structure of several species can be characterized by MAL-DI-TOF mass spectrometry [19] , the MALDIxin approach can be applied to other gramnegative pathogens in which colistin resistance is a great challenge. Table 1 summarizes the expected peaks corresponding to native and modified lipid A for organisms in which colistin resistance is prevalent and this approach has been tested. The MALDIxin test is particularly effective for Acinetobacter baumannii, successfully detecting resistant strains with minimal sample preparation [21] , as well as K. pneumoniae, for which, despite the requirement for a brief mild acid hydrolysis step, this method provides rapid and accurate identification of colistin resistance [22] . Although acid hydrolysis of the sample was not initially performed for E. coli and A. baumannii [20, 21] , routine application of this step during sample preparation results in improved signal-to-noise ratio, especially for more complex bacteria like K. pneumoniae [22] while allowing uniform sample processing of any organism of interest.
In addition to the MALDIxin test, an alternative (albeit more time-consuming) strategy for lipid A characterization in the context of MALDI-TOF-based diagnostics was recently presented [23] . This approach relies on extraction of lipid A from bacterial samples followed by MALDI-TOF analysis of the extracts and was shown to allow the pairing of bacterial identification [24] with colistin resistance detection [23] . The method has since been employed in a prospective study monitoring colistin susceptibility in clinical A. baumannii isolates, proving that these approaches have clinical utility [25, 26] .
MALDI-TOF-based diagnostics can be used for rapid detection of colistin resistance in clinical settings
Although fast and effective, all MALDI-TOF-based methods for detecting colistin resistance were initially developed using research mass spectrometers and were not tested on the instruments commonly used in clinical settings. The main reason for this was that until recently, clinically used mass spectrometers could not operate in the negative-ion mode. The latest model of the widely used MALDI Biotyper system by Bruker Daltonics, the MALDI Biotyper Sirius, is equipped with a negative-ion mode, permitting the recent adaptation of the MAL-DIxin test for the type of instruments used in hospitals [18] .The sample preparation step was optimized for E. coli strains to maximize the signal-to-noise ratio without compromising the speed of the method (Fig 2) . Calculation of PRR values from recorded spectra, taking into account the peaks arising from the addition of PEtN and/or L-Ara4N moieties to lipid A (Fig  1, right column and Table 1 ), allowed rapid and accurate identification of colistin resistance irrespective of its genetic basis in clinical E. coli isolates. As before, colistin-susceptible strains gave a PRR value of zero, and positive PRR values indicated resistance to colistin. Ultimately, this feasibility study showed that MALDI-TOF-based detection of colistin resistance using a clinical mass spectrometer can generate an unambiguous yes/no output, thus laying the foundations for a rapid diagnostic test that will be readily accessible to most clinical microbiology laboratories.
Future directions
There is no doubt that MALDI-TOF-based approaches offer considerable promise for the development of rapid diagnostics for the detection of colistin resistance. The recent advances described here allow the introduction of such methods in clinical settings with the hope that they might eventually become the gold standard for polymyxin susceptibility testing. To achieve this, it is important to expand the range of gram-negative bacteria for which MALDI-TOF-based methods can be applied. This would include tests on organisms that have not been extensively characterized by MALDI-TOF mass spectrometry, like Pseudomonas, Enterobacter, Citrobacter, and Burkholderia spp., and further optimization of the sample preparation pipeline so that clinical instruments like the MALDI Biotyper Sirius system would be effectively used for all organisms of interest.
For such approaches to truly reach the clinic, further validation in hospital settings using large numbers of clinical isolates will be essential in order to pinpoint any discrepancies between MIC data and MALDI-TOF-based diagnostics (for example, it is known that in rare cases, colistin resistance in A. baumannii is due to total absence of lipid A [27] or efflux pump activity [28] ). Large-scale testing will also promote the delineation of specific ranges for the metrics used to analyze and evaluate the acquired spectra, enabling clinical microbiologists to make confident calls regarding susceptibility or resistance to colistin in a similar manner as when using the antibiotic breakpoints defined by the European Committee for Antimicrobial Susceptibility Testing (EUCAST). This will have to be achieved in tandem with automation of the data analysis process, which will permit high-throughput processing of the samples. Some Table 1 . m/z values rounded to the nearest decimal for native and modified lipid A peaks obtained by MALDI-TOF mass spectrometry from intact colonies of gram-negative bacterial pathogens that are commonly resistant to colistin. PLOS PATHOGENS effort has already been made towards this in a study showing that machine learning algorithms and MALDI-TOF mass spectrometry can be used to detect colistin-resistant Acinetobacter and Klebsiella spp. in complex polymicrobial mixtures [29] . The total sample processing time using this approach is less than 15 minutes, allowing for immediate assessment of whether bacteria are resistant to polymyxin antibiotics, independent of the mechanism of resistance. In the published feasibility study [18] , bacterial colonies were grown overnight on solid medium; in future clinical applications, bacteria could be obtained directly from biological samples, such as urine or blood. Figure created with BioRender.
Organism Native lipid A peak(s) (m/z) Modified lipid A peak(s) (m/z) Lipid A modification
https://doi.org/10.1371/journal.ppat.1008331.g002
PLOS PATHOGENS
Overall, MALDI-TOF-based diagnostics applied for the detection of polymyxin resistance offer major advantages and could become a clinical reality. The strength of these approaches is that they could serve as a first-line strategy to rapidly, reliably, and cost-effectively identify colistin resistance with minimal changes to existing clinical equipment and workflows. It is expected that MALDI-TOF mass spectrometers with negative-ion mode capabilities approved for routine clinical use will make their way into hospital laboratories as part of the regular equipment upgrade cycle, allowing the implementation of this approach alongside existing positive-ion mode applications. If required for epidemiological purposes, in-depth characterization of the isolated strains could be pursued at a second stage using culture-, PCR-or sequencing-based methods. This type of pipeline would ensure that treatment of patients with challenging MDR gram-negative infections happens as efficiently as possible, improving patient outcomes without compromising the necessary epidemiological component of clinical microbiology.
